Reneo Pharmaceuticals to Participate in SVB Leerink Virtual Global Healthcare Conference

Rhea-AI Summary

Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM) announced its participation in SVB Leerink’s Virtual Global Healthcare Conference from February 14-18, 2022. A fireside chat is scheduled for February 18, 2022, at 1:00 PM ET. The company focuses on developing therapies for rare genetic mitochondrial diseases, with its lead product, REN001, aimed at enhancing mitochondrial function and ATP production. Reneo's innovations could significantly impact the treatment landscape for patients suffering from these conditions.

IRVINE, Calif., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases, today announced that it will be hosting a fireside chat and participating in one-on-one investor meetings at SVB Leerink’s Virtual Global Healthcare Conference taking place February 14-18, 2022.

Presentation details are as follows:

Date: Friday, February 18, 2022
Time: 1:00 PM ET
Format: Fireside chat

About Reneo Pharmaceuticals

Reneo is a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). Reneo is developing REN001 to modulate genes critical to metabolism and generation of ATP, which is the primary source of energy for cellular processes. REN001 has been shown to increase transcription of genes involved in mitochondrial function and increase fatty acid oxidation, and may increase production of new mitochondria.

Contacts:

Joyce Allaire
Managing Director
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com

Vinny Jindal
Chief Financial Officer
Reneo Pharmaceuticals, Inc.
investors@reneopharma.com

 

FAQ

What is Reneo Pharmaceuticals participating in on February 14-18, 2022?

Reneo Pharmaceuticals is participating in SVB Leerink’s Virtual Global Healthcare Conference.

When is Reneo Pharmaceuticals' fireside chat scheduled?

The fireside chat is scheduled for February 18, 2022, at 1:00 PM ET.

What does Reneo Pharmaceuticals focus on?

Reneo Pharmaceuticals focuses on developing therapies for rare genetic mitochondrial diseases.

What is REN001 and its purpose?

REN001 is Reneo Pharmaceuticals' lead product aimed at enhancing mitochondrial function and ATP production.

How does REN001 affect mitochondrial function?

REN001 has been shown to increase the transcription of genes involved in mitochondrial function and may boost the production of new mitochondria.